SG11201601150WA - Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors - Google Patents
Peptidyl nitril compounds as dipeptidyl peptidase i inhibitorsInfo
- Publication number
- SG11201601150WA SG11201601150WA SG11201601150WA SG11201601150WA SG11201601150WA SG 11201601150W A SG11201601150W A SG 11201601150WA SG 11201601150W A SG11201601150W A SG 11201601150WA SG 11201601150W A SG11201601150W A SG 11201601150WA SG 11201601150W A SG11201601150W A SG 11201601150WA
- Authority
- SG
- Singapore
- Prior art keywords
- peptidyl
- inhibitors
- dipeptidyl peptidase
- nitril
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13183519 | 2013-09-09 | ||
EP14151979 | 2014-01-21 | ||
PCT/EP2014/069088 WO2015032945A1 (en) | 2013-09-09 | 2014-09-08 | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201601150WA true SG11201601150WA (en) | 2016-03-30 |
Family
ID=51535425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201601150WA SG11201601150WA (en) | 2013-09-09 | 2014-09-08 | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
Country Status (10)
Country | Link |
---|---|
US (1) | US9856228B2 (ja) |
EP (1) | EP3044214B1 (ja) |
JP (1) | JP6408008B2 (ja) |
CN (1) | CN105612149A (ja) |
AU (1) | AU2014317048B2 (ja) |
CA (1) | CA2923484C (ja) |
DK (1) | DK3044214T3 (ja) |
EA (1) | EA029030B1 (ja) |
SG (1) | SG11201601150WA (ja) |
WO (2) | WO2015032945A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014317048B2 (en) | 2013-09-09 | 2018-05-10 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors |
NO2699580T3 (ja) | 2014-01-24 | 2018-02-24 | ||
CA2978234C (en) * | 2015-03-05 | 2023-05-02 | Prozymex A/S | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
US10968185B2 (en) * | 2015-04-07 | 2021-04-06 | Ela Pharma Ltd. | Substituted thiazoles for preventing and/or treating cell or tissue necrosis |
KR20210032431A (ko) | 2018-07-17 | 2021-03-24 | 인스메드 인코포레이티드 | 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010006110A (es) * | 2007-12-12 | 2010-06-25 | Astrazeneca Ab | Peptidil-nitrilos y usos de los mismos como inhibidores de la dipeptidil-peptidasa i. |
KR100903499B1 (ko) | 2007-12-27 | 2009-06-18 | 엔에이치엔비즈니스플랫폼 주식회사 | 검색 의도 분류에 따른 광고 제공 방법 및 상기 방법을수행하기 위한 시스템 |
JP2012526093A (ja) * | 2009-05-07 | 2012-10-25 | アストラゼネカ・アクチエボラーグ | 置換1−シアノエチルヘテロシクリルカルボキサミド化合物750 |
WO2010142985A1 (en) | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
WO2011154677A1 (en) | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
WO2012130299A1 (en) | 2011-03-30 | 2012-10-04 | Prozymex A/S | Peptidase inhibitors |
US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
AU2014317048B2 (en) | 2013-09-09 | 2018-05-10 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors |
-
2014
- 2014-09-08 AU AU2014317048A patent/AU2014317048B2/en active Active
- 2014-09-08 JP JP2016539571A patent/JP6408008B2/ja active Active
- 2014-09-08 WO PCT/EP2014/069088 patent/WO2015032945A1/en active Application Filing
- 2014-09-08 CA CA2923484A patent/CA2923484C/en active Active
- 2014-09-08 EP EP14761986.0A patent/EP3044214B1/en active Active
- 2014-09-08 WO PCT/EP2014/069081 patent/WO2015032943A1/en active Application Filing
- 2014-09-08 SG SG11201601150WA patent/SG11201601150WA/en unknown
- 2014-09-08 EA EA201690561A patent/EA029030B1/ru not_active IP Right Cessation
- 2014-09-08 DK DK14761986.0T patent/DK3044214T3/da active
- 2014-09-08 US US14/917,147 patent/US9856228B2/en active Active
- 2014-09-08 CN CN201480049595.8A patent/CN105612149A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2014317048B2 (en) | 2018-05-10 |
WO2015032945A1 (en) | 2015-03-12 |
CA2923484C (en) | 2022-09-06 |
EA029030B1 (ru) | 2018-01-31 |
US20160207900A1 (en) | 2016-07-21 |
EP3044214A1 (en) | 2016-07-20 |
NZ718128A (en) | 2021-04-30 |
EP3044214B1 (en) | 2017-08-09 |
DK3044214T3 (da) | 2017-11-13 |
CA2923484A1 (en) | 2015-03-12 |
JP2016529306A (ja) | 2016-09-23 |
US9856228B2 (en) | 2018-01-02 |
WO2015032943A1 (en) | 2015-03-12 |
CN105612149A (zh) | 2016-05-25 |
JP6408008B2 (ja) | 2018-10-17 |
AU2014317048A1 (en) | 2016-04-07 |
EA201690561A1 (ru) | 2016-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190373T1 (hr) | Inhibitori dnk-pk | |
IL265611A (en) | (S2)–N–[S)1)–1–cyano–2–phenylethanyl]–1,4–oxazaphene–2–carboxamides as dipeptidyl peptidase 1 inhibitors | |
HK1212696A1 (zh) | 抑制劑 | |
EP2948450A4 (en) | METALLOENZYMINHIBITORVERBINDUNGEN | |
IL265496A (en) | bace1 inhibitors | |
HK1216531A1 (zh) | 新的抑制劑 | |
EP2824110A4 (en) | DIPEPTIDYL PEPTIDASE-IV INHIBITOR | |
SG11201601150WA (en) | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors | |
DK3265452T3 (en) | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors | |
HK1217950A1 (zh) | 新型 抑制劑 |